Last reviewed · How we verify

NXY-059 — Competitive Intelligence Brief

NXY-059 (NXY-059) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Free radical scavenger / Neuroprotective agent. Area: Neurology.

phase 3 Free radical scavenger / Neuroprotective agent Reactive oxygen species (ROS) / Free radicals Neurology Small molecule Live · refreshed every 30 min

Target snapshot

NXY-059 (NXY-059) — AstraZeneca. NXY-059 is a free radical-trapping agent that scavenges harmful free radicals produced during ischemic stroke to reduce neuronal damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NXY-059 TARGET NXY-059 AstraZeneca phase 3 Free radical scavenger / Neuroprotective agent Reactive oxygen species (ROS) / Free radicals

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Free radical scavenger / Neuroprotective agent class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NXY-059 — Competitive Intelligence Brief. https://druglandscape.com/ci/nxy-059. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: